Navigation Links
AbbVie Reports Second-Quarter 2014 Financial Results
Date:7/25/2014

taining BRCA1 and/or BRCA2 gene mutations.  The trial will recruit approximately 270 patients.  The primary efficacy outcome is progression-free survival.  The secondary pre-specified outcome measures include overall survival, clinical benefit rate, objective response rate and duration of response. The start of this trial followed initiation of Phase 3 clinical work in two other settings: non-small cell lung cancer and neoadjuvant treatment of triple negative breast cancer.
  • Biogen Idec and AbbVie announced positive top-line results from the Phase 3 DECIDE trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process (DAC HYP) when compared to intramuscular interferon beta-1a (IFN β-1a), as a potential treatment for relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis.  Results showed that DAC HYP was superior on the study's primary endpoint, demonstrating a statistically significant 45 percent reduction in annualized relapse rate (ARR) compared to IFN β-1a (p<0.0001). 
  • AbbVie presented interim results from a Phase 1b clinical trial of ABT-199/GDC-0199, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab.  Results showed an overall response rate of 84 percent, in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).  These results were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO).  The combination of ABT-199/GDC-0199 and rituximab is being investigated in an ongoing Phase 3 clinical trial for the treatment of relapsed/refractory CLL.
  • AbbVie presented updated data from another Phase 1 study of ABT-199/GDC-0199 as a monotherapy including results from the trial arms investigating the compound as a treatment for patients with relapsed/refractory CLL and a variety of subtypes of non-Hodgkin's ly
    '/>"/>

  • SOURCE AbbVie
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

    Related medicine technology :

    1. AbbVie to Host Second-Quarter Earnings Conference Call
    2. AbbVie to Host Fourth-Quarter and Full-Year 2013 Earnings Conference Call
    3. AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C
    4. AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy
    5. U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVies Humira, as a Result of Its Recent Approval in Ulcerative Colitis
    6. Financial Results, New Drug Applications, and Stock Price Movements - Research Report on Endo, Bristol-Myers Squibb, Express Scripts, AbbVie, and Incyte
    7. AbbVie Reports Third-Quarter 2013 Financial Results
    8. AbbVie Named a Science Top Employer
    9. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
    10. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
    11. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/17/2015)... April 17, 2015  Trovagene, Inc., (NASDAQ:  TROV) ... that clinical data presented at the 2015 European ... Precision Cancer Monitoring ℠ (PCM) platform outperformed ... EGFR T790M mutations in metastatic lung ... EGFR T790M Mutation in Urinary Circulating Tumor DNA ...
    (Date:4/17/2015)... 17, 2015 Steven Rash , the CEO ... its operating subsidiary American Seed & Oil Company, presented ... investors yesterday in New York City.  Mr. Rash,s presentation ... American Seed & Oil Company has recently announced the ... Hemp Seed Foods , the EpiVape , and ...
    (Date:4/17/2015)... , Apr. 16, 2015 Research and Markets ... of the "Corporate Reputation of Pharma in 2014 ... 1st Edition" report to their offering. ... compared opinions on the corporate reputation of the pharmaceutical ... mental health with the views of patient organisations representing ...
    Breaking Medicine Technology:Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3
    ... 23, 2011 Dr. Michael Hayden, a Xenon founder ... Wightman Award for leadership in medical science in Canada. ... for Dr. Hayden, having previously been awarded the Order ... Institutes of Health Research,s Health Researcher of the Year ...
    ... 22, 2011 Boston Scientific Corporation (NYSE: BSX ... on April 4, 2011 at the 60th Annual Scientific Session ... The Company will provide an update on its Cardiology, Rhythm ... heart technologies.  The event is scheduled to begin at 6 ...
    Cached Medicine Technology:Xenon Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine 2
    (Date:4/19/2015)... Indiana (PRWEB) April 19, 2015 ... statewide Network Service Provider, announces a major bandwidth ... (AdamsWells) in Bluffton, IN. Craigville Telephone Company, ... has expanded service on IFN’s protected 10 Gigabit ... Zehner, IFN’s Vice President of Sales and Marketing, ...
    (Date:4/18/2015)... CA (PRWEB) April 19, 2015 For some ... will proudly display for the rest of their lives, as ... obtaining them and put in a great amount of thought ... a whim, they have outgrown them or simply want them ... of people regret their tattoo, and in 2012-13 there was ...
    (Date:4/18/2015)... Carinsurancequotesinfo.com has released a new blog post ... caused by a car accident. , Car ... vehicle. A policy can pay for car repairs and ... always carry appropriate coverage when they are driving. ... with several important riders that offer extra coverage options. ...
    (Date:4/18/2015)... 18, 2015 "I recognized the need ... healthcare facilities," said an inventor from Cincinnati, Ohio. "This ... , He developed the Slyde Door to offer an ... healthcare facilities. It provides convenient storage space for an ... stretchers available for patients. , This offers added ...
    (Date:4/18/2015)... Insuranceautoquote.info has released a new blog post explaining how ... , Clients can review important auto insurance quotes online, ... important advantages for clients who need affordable financial security ... have coverage for their vehicles can purchase a policy ... Many agencies offer important discounts and drivers can learn ...
    Breaking Medicine News(10 mins):Health News:AdamsWells Internet Telecom TV Expands Bandwidth via Indiana Fiber Network, LLC 2Health News:Dennis Dass, M.D. is Shattering the Past While Revealing the Future 2Health News:Auto Insurance Plans Can Cover Physical Injuries Caused By An Accident! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2
    ... to reduce transmission from mother to child, experts say ... HIV infection in infants are significantly higher among blacks ... to reduce the disparity, a new government report says. ... overall, among black babies, the rate of perinatal HIV ...
    ... , SACRAMENTO, Calif. , Feb. 4 ... CEO and Meg Heim, RN , Vice President of Marketing ... Force Committee on behalf of the Governor of California , ... California Department of Chronic Disease and Injury Prevention (CDPH).  The committee ...
    ... , ATLANTA , Feb. 4 ... Financial Management Association (HFMA) performed a rigorous assessment of ... by Surgical Information Systems, and determined that it meets ... the areas of effectiveness, quality and usability, price, value, ...
    ... , HAMILTON, Bermuda , ... ("XL" or the "Company") today announced that Chief Executive,Officer Michael S. ... 2010 at the Mandarin Oriental Hotel in Miami, Florida ,on ... A live webcast of Mr. McGavick,s presentation will ...
    ... , , EDF Testifies 20 Million+ Residents in South ... Calif. , Feb. 4 Environmental Defense Fund ... Standard (NAAQS) for ozone pollution from 75 to 60 parts ... reduce asthma cases 50-fold, according to analyses by the Environmental Protection ...
    ... (Feb. 4, 2010) Patients with mild gallstone pancreatitis usually ... symptoms to subside, before undergoing surgery to remedy the condition. ... Institute (LA BioMed) indicates patients may no longer have to ... sooner. The study, slated for publication in the ...
    Cached Medicine News:Health News:Black and Hispanic Infants Much More Likely to Have HIV 2Health News:BioMedix Vascular Solutions, Inc. Invited to Participate in the California P.A.D. Task Force Committee 2Health News:SIS Rules-Based Charging Solution Successfully Peer Reviewed by HFMA for Third Consecutive Year 2Health News:SIS Rules-Based Charging Solution Successfully Peer Reviewed by HFMA for Third Consecutive Year 3Health News:XL Capital Ltd to Present at Credit Suisse Financial Services Forum on February 11, 2010 2Health News:Stronger Ozone Standard Could Dramatically Reduce Asthma, Premature Deaths 2Health News:Stronger Ozone Standard Could Dramatically Reduce Asthma, Premature Deaths 3Health News:Patients with mild gallstone pancreatitis can undergo surgery sooner, shortening hospital stays 2
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: